75 related articles for article (PubMed ID: 9156411)
1. Prevention of recurrences after deep venous thrombosis: role of low-molecular-weight heparins.
Pini M
Semin Thromb Hemost; 1997; 23(1):51-4. PubMed ID: 9156411
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
3. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
4. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
5. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
6. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
Cziraky MJ; Spinler SA
Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis.
Holmström M; Aberg W; Lockner D; Paul C
Thromb Haemost; 1999 Oct; 82(4):1222-6. PubMed ID: 10544902
[TBL] [Abstract][Full Text] [Related]
12. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
[TBL] [Abstract][Full Text] [Related]
13. Treatment of deep vein thrombosis with low-molecular-weight heparins: a consensus statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH).
Harenberg J; Schmitz-Huebner U; Breddin KH; Hass S; Heinrich F; Heinrichs C; Kienast J; Roebruck P; Theiss W; Wenzel E
Semin Thromb Hemost; 1997; 23(1):91-6. PubMed ID: 9156416
[TBL] [Abstract][Full Text] [Related]
14. [Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis].
Marbet GA
Ther Umsch; 1992 Dec; 49(12):843-9. PubMed ID: 1336627
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparin in outpatient treatment of DVT.
Yeager BF; Matheny SC
Am Fam Physician; 1999 Feb; 59(4):945-52. PubMed ID: 10068716
[TBL] [Abstract][Full Text] [Related]
16. The role of low molecular weight heparin in total knee arthroplasty.
Iobst CA; Friedman RJ
Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook].
Fiessinger JN
Bull Acad Natl Med; 1997 May; 181(5):875-83; discussion 883-5. PubMed ID: 9312362
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
19. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
[TBL] [Abstract][Full Text] [Related]
20. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
